ampelopsin has been researched along with Carcinoma, Non-Small Cell Lung in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 2 (40.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lu, L; Qin, H; Song, CL; Wang, XX; Wu, YJ; Yang, LN | 1 |
| Ahn, BN; Hong, SW; Hur, DY; Kim, D; Kim, YS; Lee, HK; Noh, MH; Park, NS; Shim, JA | 1 |
| Bian, W; Guan, X; Jiang, J; Li, W; Sun, Y; Wang, Y; Xu, C; Yu, X; Zhang, C; Zhao, Q | 1 |
| Li, W; Li, X; Wang, R; Zhang, Y; Zhou, L | 1 |
| Chang, JH; Chien, MH; Chow, JM; Chung, CL; Hung, WY; Kao, SJ; Lee, WJ | 1 |
5 other study(ies) available for ampelopsin and Carcinoma, Non-Small Cell Lung
| Article | Year |
|---|---|
Synergistic cytotoxicity of ampelopsin sodium and carboplatin in human non-small cell lung cancer cell line SPC-A1 by G
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Flavonoids; Humans; Lung Neoplasms | 2017 |
Combination treatment with erlotinib and ampelopsin overcomes erlotinib resistance in NSCLC cells via the Nox2-ROS-Bim pathway.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Clinical Trials as Topic; Combined Modality Therapy; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Flavonoids; Humans; Lung Neoplasms; Mutation; NADPH Oxidase 2; Protein Kinase Inhibitors; Reactive Oxygen Species; RNA, Small Interfering | 2017 |
The mechanism of rh-endostatin-induced cardiotoxicity and its protection by dihydromyricetin[in vivo/in vitro, C57BL/6 mice, AC16 and hiPSC-CMs].
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Cardiotoxicity; Drug-Related Side Effects and Adverse Reactions; Endostatins; Humans; Induced Pluripotent Stem Cells; Lung Neoplasms; Mice; Mice, Inbred C57BL; Myocytes, Cardiac | 2023 |
Dihydromyricetin suppresses tumor growth via downregulation of the EGFR/Akt/survivin signaling pathway.
Topics: Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Down-Regulation; ErbB Receptors; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Signal Transduction; Survivin | 2023 |
Suppression of reactive oxygen species-mediated ERK and JNK activation sensitizes dihydromyricetin-induced mitochondrial apoptosis in human non-small cell lung cancer.
Topics: A549 Cells; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Survival; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Enzyme Activation; Extracellular Signal-Regulated MAP Kinases; Flavonols; Humans; JNK Mitogen-Activated Protein Kinases; Lung Neoplasms; MAP Kinase Signaling System; Membrane Potential, Mitochondrial; Mitochondria; Protein Kinase Inhibitors; Reactive Oxygen Species | 2017 |